TheraRadar
← Back
Data updated: Jul 17, 2026

MEDLINE INDUSTRIES

Pharma
DermatologyGastroenterology Execution: Excellent

MEDLINE INDUSTRIES is a pharmaceutical company focused on Dermatology, Gastroenterology. Key products include READYPREP CHG.

2018
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

MEDLINE INDUSTRIES at a Glance

  • Strong track record with 93% execution quality across 17 trials
  • Fast trial execution (6 months median completion)

MEDLINE INDUSTRIES's Key Drugs

MEDLINE INDUSTRIES's core commercial portfolio centers on READYPREP CHG, spanning Dermatology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

READYPREP CHG
Infectious Disease
Approved 2018

MEDLINE INDUSTRIES's Recent FDA Approvals

New NDA/BLA approvals for MEDLINE INDUSTRIES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MEDLINE INDUSTRIES's Therapeutic Areas

MEDLINE INDUSTRIES's approved drugs and pipeline span 2 therapeutic areas, led by Dermatology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 75%
0 drugs Phase 2: 1 Phase 1: 1
Gastroenterology 25%
0 drugs Phase 1: 1

MEDLINE INDUSTRIES's Top Competitors

MEDLINE INDUSTRIES's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, APOTHECON, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

BAUSCH specialty
Dermatology, Gastroenterology
APOTHECON specialty
Dermatology, Gastroenterology
PF PRISM CV big-pharma
Dermatology, Gastroenterology
MALLINCKRODT specialty
Gastroenterology, Dermatology
LEGACY big-pharma
Gastroenterology, Dermatology

MEDLINE INDUSTRIES Pipeline Snapshot

MEDLINE INDUSTRIES has 3 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 2 Phase 1.

0
Phase 3
1
Phase 2
2
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • READYPREP CHG leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Dermatology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 4/4 completed
  • • Speed: 6 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges